disease-related genes may be involved. Despite considerable research advances for the genetic and molecular backgrounds of ARVC, the pathophysiological mechanisms still remain to be fully elucidated. 5 Rho-kinase, the major downstream effector of the small GTPase Rho, is a protein kinase that has recently attracted much attention in the cardiovascular research field. 6 Abnormalities of the Rho/Rho-kinase pathway have been implicated in the pathogenesis of several cardiovascular disorders in human and animal studies. 7 Rho-kinase regulates a wide range of cellular functions, including actin cytoskeleton assembly, cell contractility, proliferation and differentiation, and gene expression. 8, 9 In addition, the Rho/Rho-kinase system plays an important role in the regulation of adipogenesis. 10 Indeed, the Rho/Rhokinase system has been shown to negatively regulate adipogenesis through interacting with Wnt signaling 11 and, in part, by controlling the expression of pro-and antiadipogenic Wnt genes. 10 Activation of canonical Wnt/β-catenin signaling is known to inhibit adipogenesis. 10 The less well-characterized noncanonical β-catenin-independent pathway, which involves activation of small G proteins and their downstream effectors, including the Rho/Rho-kinase system, plays a more complex role. 12 Interestingly, downregulated Wnt signaling has been recently implicated in the development of ARVC in mice. [13] [14] [15] Because systemic Rho-kinase disruption in mice results in perinatal lethality, it has been difficult to examine the specific role of Rho-kinase in the cardiovascular system in mouse models. Thus, in the present study, we developed a novel mouse model in which Rho-kinase deficiency was targeted to the cardiovascular system during development. We here show that these Rho-kinase-deficient mice spontaneously develop unique phenotypes fulfilling the criteria of ARVC in humans associated with altered desmosome structure and aberrant Wnt signaling, indicating a novel and crucial role for Rhokinase inhibition during development in the pathogenesis of ARVC in mice.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Inhibition of Rho-Kinase Activity in the Developing Heart Through Overexpression of Dominant-Negative Rho-Kinase
To study the role of Rho-kinase inhibition in the cardiovascular system, we generated a novel mouse model in which dominant-negative Rho-kinase (DN-RhoK) 16 was overexpressed using the Cre-loxP system ( Figure 1A and 1B) .
DN-RhoK consists of the carboxy-terminal fragment of Rhokinase, which serves as an autoregulatory inhibitor of the amino-terminal kinase domain, 17 in which 2 point mutations were introduced to suppress Rho-binding activity. 16 DN-RhoK has been shown to inhibit intrinsic Rho-kinase activity when overexpressed in vivo. 18 Overexpression of DN-RhoK in our mouse model successfully reduced the activity of Rho-kinase in the embryonic day (E) 12.5 embryonic hearts ( Figure 1C ) and in the postnatal aortas ( Figure 1D ) of DN-RhoK mice compared with controls. We noted some sudden deaths of several pups before they were weaned at the age of 4 weeks. The breeding strategy used was expected to give rise to a 50% DN-RhoK offspring ( Figure 1E) . The genotype frequencies observed on E12.5 and until 1 week after birth in DN-RhoK mice were comparable to the expected frequency, indicating the absence of embryonic or neonatal lethality in DN-RhoK mice. However, the genotype frequency of DN-RhoK mice was reduced to 30% at 4 weeks of age ( Figure 1E ). The heart weight to body weight ratio and the ventricular weight to body weight ratio were both significantly higher in DN-RhoK mice compared with controls ( Figure 1F ). Systolic blood pressure was significantly lower in DN-RhoK mice compared with controls ( Figure 1G ). In addition, the aortas of DN-RhoK mice were thinner than those of controls ( Figure 1H ).
Crucial Role of Rho-Kinase in Cardiac Development
We first examined the sections of E12.5 embryos. Interestingly, we observed a marked thinning of the ventricular walls and interventricular septum of the hearts of DN-RhoK embryos (Figure 2A ). Similar changes were noted in E14.5 hearts ( Figure 2B ) when the ventricular septation is normally completed and the heart has acquired the definite prenatal form. 19 To explore the mechanisms leading to ventricular thinning in DN-RhoK embryos, we examined cell proliferation and apoptosis in E12.5 hearts. TUNEL (TdT-mediated dUTP nick end labeling) assay showed a comparable extent of apoptosis between DN-RhoK and control hearts ( Figure 2C ). On the contrary, BrdU (bromodeoxyuridine) analysis showed a marked reduction in the number of proliferating cardiomyocytes in the ventricular walls and interventricular septum (both in compact layer and trabeculated layer) of DN-RhoK embryos and adult hearts compared with controls ( Figure 2D ).
Frequent Sudden Death and Cardiovascular Dysfunction in DN-RhoK Mice
Survival curves demonstrated a significantly higher mortality rate for DN-RhoK mice compared with controls, and by 1 year of follow-up, 34.6% of the DN-RhoK mice died suddenly ( Figure 3A ). Telemetry ECG recordings revealed significantly prolonged P-R intervals and QRS durations in DN-RhoK mice, suggesting the presence of cardiac conduction disturbances ( Figure 3B ). Interestingly, frequent spontaneous ventricular arrhythmias were detected in all the DN-RhoK mice examined, but not in the controls ( Figure 3C ). These spontaneous ventricular arrhythmias were evident as long frequent runs of ventricular extrasystoles characterized by widened QRS complexes with no apparent association with the P waves ( Figure 3D developed sustained ventricular tachycardia and fibrillation and died suddenly during the telemetry ECG follow-up ( Figure 3E ). We further examined the effects of Rho-kinase inhibition on cardiovascular performance in DN-RhoK mice. Echocardiographic evaluation of DN-RhoK mice revealed dilated ventricular chambers, especially the RV ( Figure 4A ). Furthermore, DN-RhoK mice showed increased RV and LV dimensions and reduced LV ejection fraction and fractional shortening compared with controls ( Figure 4B ), suggesting the involvement of the LV in the cardiac phenotypes of DN-RhoK mice.
Myocardial Fibrofatty Changes in DN-RhoK Mice
We next examined the morphological changes in the heart after birth ( Figure 4C ). Interestingly, the hearts of DN-RhoK mice were markedly dilated as early as postnatal day 3. The dilatation was more prominent in the RV and was progressive with age ( Figure 5A ). Cross sections at the level of the ventricles showed a progressive ventricular dilatation and thinning in DN-RhoK hearts, more prominent in the RV, evident from postnatal day 3 ( Figure 5A ). In contrast, the hearts from controls showed no evidence of ventricular dilatation or thinning ( Figure 5B ). Myocardial fibrotic changes, though minimal, were evident as early as postnatal day 3 in both the LV and RV in DN-RhoK hearts ( Figure 5C ). The fibrosis was initially noted in epicardial and perivascular regions of the ventricles in DN-RhoK mice, progressing to the adjacent myocardium with advancing age and involving the entire thickness of the RV free wall in some areas at week 19 ( Figure 5C ). In contrast, by the age of 19 weeks, control hearts did not show any evidence of fibrotic changes in either the RV or the LV ( Figure 5D ). An additional unexpected observation was the detection of massive fat accumulation in the RV free wall adjacent to the areas of fibrosis in 19-week-old DN-RhoK hearts ( Figure 5E ), as well as small scattered clusters of fat cells in the LV. No evidence of fatty change was observed in control hearts ( Figure 5E ). Oil red O staining further confirmed the presence of fatty change mainly in the RV of DN-RhoK mice, and it was not detected in control hearts ( Figure 5F , arrows). Our DN-RhoK mice have thereby displayed remarkable and unexpected phenotypes, including cardiac dilatation and dysfunction, myocardial fibrofatty changes, and spontaneous development of ventricular arrhythmias and sudden death. Taken together, these phenotypes fulfill the criteria for ARVC in humans. 20
Abnormal Myocardial Cell-Cell Junctions in DN-RhoK Mice
ARVC is now widely accepted as a disease of the cardiac desmosome. 2 Interestingly, the Rho/Rho-kinase pathway has been shown to interact with desmosomal proteins possessing intracellular signaling functions. 21, 22 Thus, we were interested in examining the ultrastructure of myocardial cell-cell junctions, intercalated discs, where the desmosome resides. Transmission electron microscopy showed widening of the gaps at the intercalated discs in the myocardium of 25-weekold DN-RhoK mice ( Figure 5G ). In addition, the desmosomes of DN-RhoK mice were less electron-dense compared with the controls (Figure 5G ; arrows). The gap width at the desmosomes of DN-RhoK hearts was significantly increased compared with that of control hearts ( Figure 5H ). These results suggest that normal Rho-kinase function may be necessary for the integrity of cardiac desmosomes.
To further examine the desmosomal abnormalities demonstrated in our mouse model, we next examined the distribution of the desmosomal proteins in ventricular sections by immunofluorescence staining. The expression of plakoglobin was confined to the myocardial cell-cell junctions in the RVs and LVs of control mice ( Figure 6 ). On the contrary, the RVs of DN-RhoK mice displayed a markedly disorganized myocardial structure with poorly defined cell junctional areas. The plakoglobin expression was visibly reduced and, interestingly, was mostly situated at the cardiomyocyte nuclei, rather than at junctional areas ( Figure 6 ). The LV myocardial organization of DN-RhoK heart was more orderly, and though the plakoglobin expression was reduced in intensity compared with control LVs, the signal was mostly present at the myocardial cell-cell junctions ( Figure 6 ). We also stimulated neonatal rat cardiomyocytes with a selective Rho-kinase inhibitor hydroxyfasudil for 24 hours and examined the expression of plakoglobin. However, the expression of plakoglobin did not significantly change by the treatment with hydroxyfasudil (unpublished data). This will be because the impact of Rhokinase inhibition needs to be chronic during the cardiac development for changing the expression of plakoglobin in heart tissues. Additionally, the expression of Connexin43 was also reduced in DN-RhoK hearts compared with control hearts; the signal was mostly present at the myocardial cell-cell junctions ( Figure I in the online-only Data Supplement).
Significantly Altered Gene Expression Profiles in DN-RhoK Hearts
Based on the hypothesis that the Rho-kinase inhibition in DN-RhoK hearts may change the gene profiles responsible for the phenotypes of ARVC, we performed microarray analysis using the Agilent SurePrint G3 Mouse GE microarray kit. The statistical analysis by the statistical computing software R revealed that DN-RhoK hearts had significant changes in 3653 genes (1909 increased and 1744 decreased; P<0.05) compared with age-matched controls (E12.5 embryonic hearts). Hierarchical clustering analysis ( Figure II Table) and the list of top 25 gene networks (Table I and Figures III-XV in the online-only Data Supplement). Interestingly, among the top up-or downregulated genes, we found many genes associated with the formation of cytoskeleton, cellto-cell connection, or extracellular matrix (Table) , all of which are related with the Rho-kinase signaling. Moreover, several networks were related with the pathways associated with cell morphology, cellular assembly, cell-to-cell interaction, metabolism, connective tissue disorder, and organismal development ( Figure IV 
Abnormal Wnt Signaling in DN-RhoK Mice
Wnt signaling abnormalities have been recently implicated in the adipogenic phenotype and the pathogenesis of ARVC in mice. [13] [14] [15] The Rho-kinase pathway has been shown to regulate adipogenesis through interactions with Wnt signaling. 10, 11, 23 Thus, we examined the mRNA levels of several genes related to Wnt signaling and adipogenesis. In DN-RhoK mice, the expression levels of peroxisome proliferator activated receptor-γ (PPARγ; Pparg), the master regulator of adipogenesis, 24 and Wnt5b (Wnt5b), a proadipogenic noncanonical Wnt ligand, 25 were significantly increased in E12.5 hearts compared with control hearts ( Figure 7A ). In addition, the mRNA level of β-catenin (Ctnnb1) and its downstream signaling Axin2 (Axin2), the central transcriptional regulator of canonical Wnt/β-catenin signaling, 26 was significantly increased in the E12.5 hearts and in the RV of 3-week-old DN-RhoK mice ( Figure 7A ; Figure XVIII in the online-only Data Supplement). We further examined the mRNA expression of cardiac stress markers. The expression of connective tissue growth factor (Ctgf), one of the earliest growth factors induced in cardiomyocytes in response to hypertrophic stimuli 27 and a powerful profibrotic cytokine, 28 was increased in the 3-week-old RV ( Figure 7B ). The increased expression of connective tissue growth factor was consistent with the fibrotic changes observed in the hearts of DN-RhoK mice. In addition, the expression of cardiac stress markers, such as atrial natriuretic peptide (Nppa) and b-type natriuretic peptide (Nppb), were increased in both the embryonic hearts and the 3-week-old RVs ( Figure 7B ).
Because inhibition of Wnt/β-catenin signaling has been demonstrated in several mouse models of ARVC, [13] [14] [15] we further examined the protein levels of Wnt5b, PPARγ, and β-catenin in the DN-RhoK hearts. The protein level of PPARγ in the LV and interventricular septum was comparable between the DN-RhoK hearts and controls ( Figure 7C ; Figure XVI in the online-only Data Supplement). In contrast, PPARγ levels in the RV were significantly increased in the DN-RhoK hearts compared with controls, pointing toward adipogenic phenotypic change ( Figure 7C ; Figure XVI in the online-only Data Supplement). Consistently, plakoglobin protein levels were almost half in the DN-RhoK hearts compared with controls ( Figure 7D ; Figure XVI in the online-only Data Supplement), which is consistent with the immunostaining that revealed a markedly disorganized myocardial structure with poorly defined cell junctional areas ( Figure 6 ). Finally, the downregulation of Rho-kinase activity in DN-RhoK postnatal hearts was mild, probably because of considerable involvement of fibrofatty tissues in DN-RhoK hearts ( Figure 7E ).
No Myocardial Fibrofatty Change in αMHC-Directed DN-RhoK Mice
To further discriminate the roles of Rho-kinase inhibition before (SM22α-directed) and after (αMHC-directed) the birth, we also developed mice with αMHC most probably inhibited after birth in the hearts of αMHCdirected DN-RhoK mice. In contrast, SM22α is strongly expressed in the developing heart, 30 especially in the RV, thereby inhibiting Rho-kinase activity during embryogenesis in SM22α-directed DN-RhoK mice. Thus, the present findings suggest that Rho-kinase inhibition during early cardiac development promotes abnormal phenotypic changes in the heart, resulting in ARVC.
Discussion
The present study is the first report to implicate Rho-kinase inhibition in the development of ARVC in mice. We have generated a novel mouse model in which Rho-kinase activity is inhibited in the developing heart as early as E7.5. 31 Our DN-RhoK mainly caused cardiac dilatation and dysfunction, myocardial fibrofatty changes, ventricular arrhythmias, and sudden death, fulfilling the criteria for ARVC in humans. 20 Several mouse models of ARVC involving desmosomal gene alterations have been previously developed, including desmoplakin, 13 junction plakoglobin, 14 desmoglein-2, 32 and plakophilin-2. 33 These models have provided additional support to the currently acceptable concept that ARVC is a disease of the desmosome. However, approximately half of the ARVC patients do not harbor any known causative gene mutations, 4 suggesting the involvement of other associated mechanisms. Indeed, the present study suggests that diminished activation of a Rho-kinase signaling pathway could contribute to disease development of ARVC in mice. The recent recognition of the involvement of aberrant Wnt signaling in ARVC pathogenesis in mice 13 support our findings because the Rho/Rho-kinase system are intracellular regulators involved in Wnt signaling pathways. 26 However, there are no previous reports that suggested the involvement of Rho-kinase in the pathophysiology of ARVC in humans. Nevertheless, a recent study aiming at characterizing the ARVC-specific myocardial transcriptome demonstrated the altered regulation of several genes related to Rho-signaling, 34 suggesting that modulation of the Rho/ Rho-kinase system may be potentially involved in the pathogenesis of ARVC in humans. The present mouse model provides evidence for the involvement of Rho-kinase inhibition in the pathogenesis of ARVC in mice and may serve as a novel model for ARVC. Structural changes in the intercalated discs and desmosomes have been reported in the hearts of ARVC patients, 35 as well as in mouse models of ARVC. 36 These changes most probably result from mechanical disruption of desmosomes secondary to mutated or defective desmosomal proteins. We observed intercalated disc changes in the hearts of our DN-RhoK mice, including less electron-dense desmosomes and widened gaps at the intercalated discs, in which Rhokinase will organize cytoskeletal filaments and supports desmosomal protein complex. Consistent with our findings, the Rho/Rho-kinase pathway has been shown to be necessary for normal desmosomal assembly. 21 In addition, recent studies have demonstrated a cross talk between the Rho/Rho-kinase pathway, on the one hand, and the intracellular signaling pathways involving the desmosomal proteins of the armadillo family, including plakophilin-2 22 and plakoglobin, on the other hand. 22 Interestingly, plakoglobin was reduced at the myocardial cell-cell junctions and the intercalated discs and was translocated to the nucleus in the RV of DN-RhoK mice. Loss of plakoglobin at the intercalated discs and reduction of protein levels may offer an explanation for the structural changes observed by electron microscopy. The nuclear relocalization of plakoglobin was similar to that observed in the mouse models developed by Garcia-Gras et al 13 and Lombardi et al, 14 where plakoglobin inhibits Wnt/β-catenin signaling through competing with β-catenin for its transcriptional targets, thereby stimulating adipogenic programming of the cardiomyocyte. In those studies, the trigger for the nuclear translocation of plakoglobin was the presence of desmosomal protein mutation. 13 In the absence of desmosomal mutation in our mouse model, the nuclear translocation of plakoglobin might be explained by the recently uncovered role for RhoA signaling in the assembly of desmosome protein complex (Figure 8 ). Godsel et al 21 have demonstrated that the RhoA-mediated actin reorganization is necessary for directing desmosomal precursors enriched in desmoplakin to sites of cell-cell contacts to be incorporated into newly forming desmosomes. In that study, pharmacological inhibition of Rho-kinase inhibited desmoplakin border accumulation. In our DN-RhoK model, microarray analysis demonstrated significant alterations in genes responsible for actin fiber assembly and cytoskeletal reorganization. Thus, considering the early embryonic Rho-kinase inhibition in our mouse model, the direction of desmoplakin-enriched desmosomal precursors to the cell border and the subsequent incorporation into newly formed desmosomes might have been impaired. Plakoglobin, which anchors desmoplakin to the intermediate filament network, will consequently fail to incorporate into the desmosome and is available to translocate to the nucleus (Figure 8 ). Nuclear plakoglobin competes with β-catenin for its transcriptional factors, thereby inhibiting Wnt/β-catenin signaling. 13 The increased protein levels of β-catenin and Axin2 in the RV of DN-RhoK mice may reflect the positive feedback.
Adipogenic replacement of the myocardium is an important pathological feature of ARVC. 37 The hearts of DN-RhoK mice exhibited marked myocardial fatty change, which is interesting because fat tissue is normally rare in the mouse heart. 38 In addition, the adipogenic phenotype has been displayed only in a few desmosomal mouse models of ARVC, with aberrations of Wnt signaling found to be involved. 13 These studies have shown that, in response to desmosomal protein mutation, the desmosomal protein plakoglobin is translocated to the nucleus, where it inhibits Wnt/β-catenin signaling through competing with β-catenin for its transcriptional targets. 14 Inhibition of Wnt/β-catenin signaling will promote adipogenesis and is believed to be responsible for a developmental myogenic-adipogenic switch in cardiac progenitor cells. 13 Those studies have also demonstrated increased expression levels of the proadipogenic noncanonical Wnt ligand, Wnt5b, and have suggested Wnt5b as a potential mediator in ARVC pathogenesis. 14 As mentioned earlier, there is an established role for the Rho/Rhokinase pathway in the regulation of adipogenesis. Inhibition of the Rho-kinase system in vitro, both pharmacologically and genetically, has been shown to promote adipogenesis. 39 In addition, the Rho-kinase system plays an important role in regulating the adipogenesis-myogenesis cell fate decision. 40 Several studies have shown that Rho-kinase regulates adipogenesis through interaction with Wnt signaling 11, 23 and, in part, by regulating the expression of pro-and antiadipogenic Wnt genes, where Rho-kinase inhibition stimulates the expression of proadipogenic Wnt genes, whereas Rho-kinase activation stimulates the expression of antiadipogenic Wnt genes. 10 In addition, recent studies have suggested that Rho-kinase is also involved in adipogenesis through regulating the expression of PPARγ, the master regulator of adipogenesis, 24 and β-catenin, the central transcriptional regulator of canonical Wnt/βcatenin signaling, 26 where Rho-kinase inhibition promotes adipogenesis through upregulating PPARγ and downregulating β-catenin. 23 In the present study, we have demonstrated that Rho-kinase inhibition was associated with a significant increase in the expression levels of Wnt5b, PPARγ, and β-catenin in the hearts of DN-RhoK mice ( Figure 7C ). Wnt5b has been shown to stimulate adipogenesis by directly increasing the expression levels of PPARγ 41 and through inhibition of Wnt/β-catenin signaling by preventing nuclear translocation of β-catenin. Microarray data also highlight a role for Tax1bp3 ( Figure VI in the online-only Data Supplement), which binds to β-catenin and inhibits its transcriptional activity. 42 Thus, the present results suggest that Rho-kinase inhibition mediates the inhibition of Wnt/β-catenin signaling, and cytoskeletal filament disorganization may be responsible for the impaired desmosomal protein complex and possibly the pathogenesis of ARVC in our mouse model (Figure 8 ).
The disease process started prenatally in our mouse model, as reflected by the cardiac structural changes. Prenatal onset has been reported in some desmosomal mouse models of ARVC. 13 In human ARVC, the diagnosis might be difficult before the age of 10 years, 1 although cases of ARVC in infants, 43 and even in the embryo, 44 have also been reported. In the present study, we have demonstrated that Rho-kinase deficiency in the embryonic heart resulted in abnormal cardiac development, involving ventricular thinning and reduced cardiac proliferation. These findings are consistent with the results of the previous studies that have used pharmacological inhibition of Rho-kinase in cultured mouse embryos, starting from E7.5 to E8.0. 45, 46 Those studies implicated Rho-kinase in the regulation of cardiac cell proliferation through controlling the expression of cell cycle proteins. 45, 46 It has been shown that Rho-kinase inhibition downregulates the expression of β-catenin and its downstream target cyclin-D1, 23 suggesting that the reduced cardiac cell proliferation mediated by Rho-kinase inhibition may be partially caused by reduced Wnt/β-catenin signaling. Our microarray data also stress the involvement of Rho-kinase functional networks related to pathways associated with cell morphology, cellular assembly, and organismal development. Among the top downregulated genes, α-actinin has been shown to colocalize with the proteins in the adherens junctions at the intercalated disc, 47 where it acts as the linkage with the actin filament. Thus, reduction of α-actinin may have induced the detachment of actin filaments at the intercalated disc and dysfunction of cell-to-cell attachment of cardiac myocytes. The Ingenuity Pathway Analysis network with the highest score showed the downregulation of transforming growth factor-β, an important growth factor for the development of various organs ( Figure VI in the onlineonly Data Supplement). Transforming growth factor-β plays a crucial role in the development of cardiac dysfunction and fibrosis after pressure overload in mice. 48 Transforming growth factor-β3 (encoded by TGFB3) is known as one of the causative genes for the development of familial ARVC. 49 These reports and our present findings suggest that the downregulation of transforming growth factor-β may have promoted the development of fibrofatty changes and the phenotypes of ARVC in DN-RhoK hearts.
Finally, we have performed experiments to examine the role of Rho-kinase in the regulation of calcium currents in myocytes of the RV. Here, it was difficult to obtain intact isolated myocytes from DN-RhoK hearts because of its fibrofatty changes and fragile structure of the RV. Thus, we used trabeculae from the RV of rats to confirm the role of Rho-kinase inhibition in the RV. Interestingly, Rho-kinase inhibition by selective Rho-kinase inhibitor, hydroxyfasudil, did not significantly reduce force nor [Ca] i in the RV trabeculae of rats ex vivo (unpublished data). To summarize the role of Rho-kinase inhibition in our DN-RhoK mice, we have shown that Rho-kinase inhibition in the developing heart results in the development of ARVC through the following 3 mechanisms (Figure 8 ). First, Rhokinase inhibition in the developing heart reduces cardiac cell proliferation and ventricular wall thickness. We consider that the attenuated myocardium fails to withstand the growing circulatory demands of the developing cardiovascular system, eventually resulting in cardiac dilatation and dysfunction. The cardiac stress is reflected by the increased expression of the profibrotic cytokine, connective tissue growth factor, resulting in a progressive myocardial fibrosis. Second, Rho-kinase inhibition possibly stimulates the expression of Wnt5b and PPARγ, which may be responsible for the myocardial fatty change in our mouse model. Third, inhibition of Rho-kinase is responsible for the abnormalities of the intercalated discs and desmosomes detected. The myocardial fibrofatty changes and the aberrant cell-cell communication may explain the ventricular arrhythmias that ultimately resulted in the sudden premature death in this ARVC model. Thus, Rho-kinase inhibition may offer an explanation for the development of the seemingly unrelated cardiac changes observed in ARVC and may justify Rho-kinase as a novel target to be explored in ARVC. Interactions between the Rho-kinase pathway and the Wnt signaling pathway would offer a plausible new insight into the pathogenesis of the important but yet incompletely understood disorder, ARVC.
Our present findings support a crucial role for Rho-kinase in cardiac development and may warn against the use of Rhokinase inhibitors during pregnancy. Rho-kinase plays a crucial role in the development of cardiovascular diseases. 6, 7 The beneficial effects of Rho-kinase inhibition for the treatment of cardiovascular disease have been demonstrated in various animal models and in humans. 6 However, based on the present study, Rho-kinase inhibitor may adversely affect the fetus, which is similar to the inhibitors of renin-angiotensin system. The renin-angiotensin system plays a crucial role during the normal pregnancy and subsequent well-being of mother and fetus. 50 Therefore, the use of renin-angiotensin system inhibitors is contraindicated in pregnant women. 50 To date, we have demonstrated that several medications, including statins, calcium channel blockers, and eicosapentaenoic acid, have an indirect inhibitory effect for Rho-kinase. 6, 7 Thus, the high dosage of these drugs during pregnancy may potentially contribute to the development of ARVC, which should be considered as a potential mechanism in the cases of unknown origin.
